Table 4.
Multilevel Model Results for Repeated Outcome Measures
| Measures | MS effect at baseline | MS effect on change during treatment phase |
MS effect on change from baseline to follow-up |
Contrast treatment phase vs. follow-up |
||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Beta | SE | p | Beta | SE | p | Beta | SE | p | Beta | SE | p | |
| Patient Recall Outcomes | ||||||||||||
| Cumulative recall | ||||||||||||
| Total amount of MS | .03 | .15 | .82 | .25 | .13 | .06 | .11 | .13 | .41 | .14 | .13 | .28 |
| No. of MS types used | .07 | .15 | .62 | .26 | .14 | .06 | .16 | .14 | .25 | .11 | .14 | .44 |
| MS bundles ≥ 2 | −.04 | .15 | .79 | .28 | .13 | .03 | .13 | .13 | .31 | .15 | .13 | .24 |
| MS bundles ≥ 3 | .29 | .23 | .20 | .17 | .18 | .36 | .08 | .18 | .68 | .09 | .18 | .62 |
| Past session recall | ||||||||||||
| Total amount of MS | −.05 | .15 | .73 | .23 | .18 | .20 | .08 | .17 | .65 | .15 | .17 | .40 |
| No. of MS types used | −.12 | .16 | .46 | .38 | .18 | .04 | .17 | .18 | .35 | .21 | .18 | .26 |
| MS bundles ≥ 2 | −.07 | .15 | .65 | .22 | .18 | .21 | .04 | .18 | .84 | .18 | .18 | .30 |
| MS bundles ≥ 3 | .12 | .19 | .52 | .13 | .23 | .58 | −.09 | .24 | .70 | .22 | .24 | .35 |
| Clinical Outcomes | ||||||||||||
| IDS-SR | ||||||||||||
| Total amount of MS | −.05 | .12 | .70 | −.03 | .13 | .81 | −.11 | .13 | .39 | .08 | .13 | .54 |
| No. of MS types used | −.03 | .13 | .82 | −.07 | .13 | .62 | −.16 | .13 | .22 | .10 | .13 | .47 |
| MS bundles ≥ 2 | −.06 | .12 | .64 | .004 | .12 | .98 | .02 | .12 | .89 | −.01 | .12 | .91 |
| MS bundles ≥ 3 | −.13 | .16 | .44 | −.03 | .15 | .85 | −.07 | .15 | .65 | .04 | .15 | .79 |
| GAF | ||||||||||||
| Total amount of MS | −.07 | .13 | .57 | .26 | .14 | .07 | .40 | .14 | .01 | −.14 | .14 | .33 |
| No. of MS types used | −.08 | .14 | .58 | .35 | .15 | .02 | .40 | .15 | .01 | −.05 | .15 | .73 |
| MS bundles ≥ 2 | −.08 | .13 | .54 | .23 | .15 | .13 | .29 | .15 | .05 | −.06 | .15 | .66 |
| MS bundles ≥ 3 | −.07 | .15 | .66 | −.02 | .17 | .89 | .17 | .17 | .31 | −.19 | .17 | .25 |
Note. Beta = standardized regression coefficients. Cumulative recall and past session recall were measured at session 7, post-treatment, and 6-month follow-up. IDS-SR and GAF were measured at pre-treatment baseline, post-treatment, and 6-month follow-up.
*
For patient recall variables, baseline indicates session 7 assessment. For mood outcomes (IDS-SR and GAF), baseline indicates pre-treatment baseline. Baseline or session 7 was the reference group.